Metagenomi Therapeutics, Inc.
MGX
$1.16
-$0.01-0.86%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -93.46M | -85.89M | -87.87M | -88.74M | -87.12M |
| Total Depreciation and Amortization | 5.16M | 5.23M | 5.32M | 5.48M | 5.52M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 14.97M | 16.16M | 15.75M | 22.94M | 22.82M |
| Change in Net Operating Assets | -12.16M | -22.73M | -22.09M | -31.31M | -38.22M |
| Cash from Operations | -85.49M | -87.23M | -88.89M | -91.62M | -97.01M |
| Capital Expenditure | -309.00K | -311.00K | -574.00K | -823.00K | -1.95M |
| Sale of Property, Plant, and Equipment | 0.00 | 37.00K | 37.00K | 37.00K | 37.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 97.19M | 83.06M | 104.07M | 100.49M | 65.32M |
| Cash from Investing | 96.88M | 82.79M | 103.53M | 99.71M | 63.41M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 167.00K | 202.00K | 202.00K | 109.00K | 109.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -492.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -240.00K | -508.00K | -558.00K | -539.00K | -352.00K |
| Cash from Financing | -73.00K | -306.00K | -356.00K | -430.00K | -735.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 11.32M | -4.74M | 14.28M | 7.66M | -34.33M |